Medical School · Year 2 · Msk Dermatology · includes a quiz and discussion video

Lecture 05: Crystal Arthropathies

Unit 2.10: Musculoskeletal and Dermatology

Learning Objectives

By the end of this lecture, students will be able to:

1. Describe the pathophysiology of gout and hyperuricemia
2. Explain the clinical features and stages of gout
3. Describe the diagnosis and management of acute gout
4. Explain urate-lowering therapy and its indications
5. Describe calcium pyrophosphate deposition disease (pseudogout)
6. Explain basic calcium phosphate deposition disease

Lecture Outline

I. Purine Metabolism and Hyperuricemia

Uric acid represents the terminal breakdown product of purine metabolism in humans, resulting from the action of xanthine oxidase on hypoxanthine and xanthine derived from the catabolism of adenine and guanine nucleotides. Humans lack the enzyme uricase, which in most other mammals converts uric acid to the more soluble allantoin, explaining the relatively high serum uric acid levels in humans compared to other species. Under normal physiological conditions, serum uric acid is maintained through a balance between production (approximately one-third from dietary purines and two-thirds from endogenous synthesis and nucleotide turnover) and excretion (approximately two-thirds through renal mechanisms and one-third through intestinal elimination). Disruption of this balance leads to hyperuricemia, defined as serum uric acid exceeding 6.8 mg/dL, the approximate saturation point for monosodium urate at physiological temperature and pH.

Hyperuricemia arises from either overproduction or underexcretion of uric acid, with underexcretion representing the predominant mechanism in approximately 90% of cases. Underexcretion results from reduced renal fractional excretion of uric acid, which may be primary (genetic variants affecting urate transporters including URAT1 and GLUT9) or secondary to medications (diuretics, low-dose aspirin, cyclosporine), chronic kidney disease, or conditions causing volume depletion. Overproduction accounts for approximately 10% of hyperuricemia and may result from increased dietary purine intake, accelerated nucleotide turnover in conditions such as myeloproliferative disorders and hemolytic anemias, tumor lysis syndrome, or rare inherited enzyme defects including hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency (Lesch-Nyhan syndrome) and phosphoribosyl pyrophosphate synthetase superactivity. Determining the mechanism through measurement of 24-hour urinary uric acid excretion may guide therapy selection.

Factors predisposing to hyperuricemia and gout demonstrate strong associations with lifestyle and comorbid conditions. Dietary factors include excessive consumption of purine-rich foods (organ meats, shellfish, red meat), alcohol (particularly beer, which is purine-rich, and spirits), and fructose-containing beverages. Obesity, metabolic syndrome, hypertension, and type 2 diabetes are strongly associated with gout, reflecting the complex metabolic interrelationships between these conditions and uric acid handling. Medications including thiazide and loop diuretics substantially increase gout risk. Male sex confers higher risk, with gout uncommon in premenopausal women due to the uricosuric effect of estrogen, explaining the rising female incidence after menopause. Genetic factors influence uric acid levels, with heritability estimated at 40-70%.

Hyperuricemia is necessary but not sufficient for gout development, as only a minority of individuals with elevated serum uric acid ever experience clinical gout. The relationship between uric acid level and gout risk is continuous, with progressively higher risk at higher levels: gout incidence is approximately 0.5% per year at uric acid 7-8 mg/dL but rises to approximately 5% per year at levels exceeding 9 mg/dL. Conditions promoting crystal formation beyond uric acid concentration include lower temperature (explaining the predilection for peripheral joints), pH changes, dehydration, and local tissue factors. Asymptomatic hyperuricemia, defined as elevated serum uric acid without clinical gout, does not require urate-lowering therapy in most cases, though treatment may be considered for very high levels or in the presence of urolithiasis.

<image>Panel A: Purine metabolism pathway diagram showing breakdown of dietary and endogenous purines through hypoxanthine and xanthine to uric acid via xanthine oxidase, with sites of action for allopurinol and febuxostat indicated as xanthine oxidase inhibitors. Panel B: Pie chart showing mechanisms of hyperuricemia with approximately 90% from underexcretion and 10% from overproduction, with specific causes listed for each category. Panel C: Risk factor diagram for hyperuricemia and gout showing dietary factors (alcohol, purines, fructose), comorbidities (obesity, metabolic syndrome, CKD), medications (diuretics), and demographics (male sex, older age). Panel D: Graph showing the relationship between serum uric acid level and annual gout incidence, demonstrating exponentially increasing risk at higher uric acid concentrations.</image>

II. Pathophysiology of Gouty Inflammation

Monosodium urate (MSU) crystal deposition occurs when serum uric acid exceeds the saturation threshold, typically 6.8 mg/dL at 37 degrees Celsius, with crystals forming preferentially in cooler peripheral joints and tissues. Crystals may deposit silently in joints and soft tissues for years before triggering clinical inflammation, and not all crystals provoke acute attacks. The initial nucleation and crystal growth requires supersaturation over extended periods, explaining why gout typically develops years after the onset of hyperuricemia. Crystals deposit in articular cartilage, synovium, tendons, and other soft tissues, forming the substrate for acute inflammatory attacks.

The acute gouty attack represents an intense inflammatory response to MSU crystals mediated primarily through the innate immune system. The process is triggered when crystals are phagocytosed by resident macrophages and synovial cells, activating the NLRP3 inflammasome, a cytoplasmic multiprotein complex. Inflammasome activation leads to cleavage and activation of caspase-1, which in turn processes pro-interleukin-1-beta (pro-IL-1beta) to its active form. Release of mature IL-1beta initiates a cascade of inflammatory events including neutrophil recruitment, which is the dominant cell type in gouty synovial fluid. Neutrophils further phagocytose crystals and release inflammatory mediators, proteases, and oxygen radicals, amplifying inflammation. The result is the intense, rapid-onset inflammation characteristic of acute gout.

The self-limited nature of acute gout, with spontaneous resolution even without treatment, reflects the eventual activation of anti-inflammatory mechanisms. Coating of MSU crystals with proteins including apolipoprotein E reduces their inflammatory potential. Macrophage differentiation shifts toward an anti-inflammatory phenotype. Neutrophils undergo apoptosis and are cleared by macrophages in a process (efferocytosis) that further promotes resolution. Transforming growth factor-beta (TGF-beta) and other anti-inflammatory mediators are released. This natural resolution typically occurs over days to two weeks but can be accelerated with anti-inflammatory treatment. Understanding these mechanisms has identified novel therapeutic targets.

Chronic tophaceous gout develops after years of inadequately controlled hyperuricemia, with progressive accumulation of urate crystals forming large deposits called tophi. Tophi represent organized collections of MSU crystals surrounded by a chronic granulomatous inflammatory reaction, with a corona of macrophages, giant cells, lymphocytes, and fibroblasts. These deposits enlarge over time and may occur in joints, bursae, tendons (particularly the Achilles tendon and finger extensors), over bony prominences (olecranon, finger pads), and in unusual sites including the ears and heart valves. Tophi cause joint destruction through direct erosion and inflammatory pannus formation resembling rheumatoid arthritis. With effective urate-lowering therapy reducing serum uric acid below the crystallization threshold, tophi gradually dissolve as crystals are cleared.

<image>Panel A: Diagram of NLRP3 inflammasome activation by monosodium urate crystals showing crystal phagocytosis by macrophage, inflammasome assembly, caspase-1 activation, IL-1beta cleavage and release, and downstream inflammatory cascade with neutrophil recruitment. Panel B: Synovial fluid during acute gout showing massive neutrophil infiltration, with inset of polarized microscopy demonstrating needle-shaped negatively birefringent MSU crystals (yellow when parallel to compensator axis). Panel C: Mechanisms of spontaneous resolution showing crystal coating with apolipoprotein E, macrophage phenotype shift, neutrophil apoptosis and efferocytosis, and anti-inflammatory cytokine release. Panel D: Tophus histology showing central amorphous urate crystal mass surrounded by palisading macrophages and multinucleated giant cells, with outer zone of chronic inflammatory cells and fibrous tissue.</image>

III. Clinical Manifestations of Gout

Acute gouty arthritis presents with dramatic, rapid-onset monoarticular inflammation, classically affecting the first metatarsophalangeal (MTP) joint in a presentation termed podagra. The attack typically begins overnight or in the early morning hours, with the patient awakening to severe pain, swelling, erythema, and warmth of the affected joint. Pain intensity is often described as the worst the patient has ever experienced, with exquisite tenderness such that even the weight of bedsheets is unbearable. The overlying skin may be so erythematous and warm that cellulitis is suspected. Systemic features including fever and leukocytosis may occur, further mimicking infection. Without treatment, the attack resolves spontaneously over one to two weeks, but treatment dramatically shortens the duration.

While the first MTP joint (podagra) is the most common site, accounting for approximately half of initial attacks and involved at some point in 90% of gout patients, other joints are frequently affected. The ankle, midfoot, and knee are common sites in lower extremity gout. Upper extremity involvement, particularly the wrist, finger joints, and elbow, occurs more frequently in established disease. Polyarticular gout affecting multiple joints simultaneously occurs more commonly in patients with long-standing disease, those with tophi, and in individuals who are elderly or have chronic kidney disease. Acute gout may involve periarticular structures including bursae (olecranon bursitis, prepatellar bursitis) and tendons.

Intercritical gout refers to the asymptomatic interval between acute attacks, during which patients have no joint symptoms despite ongoing crystal deposition. This period may last months to years after the initial attack, often creating a false sense of security. Subsequent attacks typically occur with increasing frequency if hyperuricemia remains untreated, eventually involving additional joints. The concept of intercritical gout is important because MSU crystals remain present in joints during asymptomatic periods, and advanced imaging (ultrasound, dual-energy CT) often reveals substantial crystal burden even without symptoms. This ongoing deposition drives eventual progression to chronic gout.

Chronic tophaceous gout represents the end stage of inadequately controlled disease, characterized by persistent joint inflammation, tophi, and destructive arthropathy. Tophi appear as firm, painless nodules that may be visible through the skin as yellow-white deposits. Common tophus locations include the fingers, olecranon bursa, ears (particularly the helix), and Achilles tendon. Tophi may ulcerate and discharge chalky urate material. Chronic gouty arthropathy produces polyarticular inflammatory arthritis that may mimic rheumatoid arthritis, with progressive joint destruction, deformity, and disability. Radiographic changes include characteristic punched-out erosions with overhanging edges (Martel sign), preserved joint space until late disease, and asymmetric distribution. Modern effective urate-lowering therapy has made tophaceous gout increasingly rare.

<image>Panel A: Clinical photograph of acute podagra showing the first MTP joint with marked erythema, swelling, and shiny skin appearance mimicking cellulitis. Panel B: Joint distribution diagram showing frequency of involvement in gout, with first MTP most common (90% ever involved), followed by ankle, midfoot, knee, and less commonly upper extremity joints. Panel C: Natural history timeline of untreated gout showing initial acute attacks separated by asymptomatic intercritical periods, with progressively shorter intervals and eventually continuous chronic tophaceous gout with permanent joint damage. Panel D: Tophaceous gout photographs showing subcutaneous tophi on fingers, olecranon, and ear helix, with one tophus demonstrating ulceration and discharge of chalky urate material.</image>

IV. Diagnosis of Gout

Definitive diagnosis of gout requires identification of monosodium urate crystals in synovial fluid or tissue, establishing crystal-proven gout that confirms the diagnosis with certainty. Arthrocentesis of an acutely inflamed joint yields inflammatory synovial fluid with white blood cell counts typically ranging from 10,000 to 70,000 cells per microliter with neutrophil predominance. Gram stain and culture should be performed to exclude septic arthritis, which may coexist with gout. The specimen is examined under compensated polarized light microscopy, where MSU crystals appear as needle-shaped structures with strong negative birefringence, meaning they appear yellow when aligned parallel to the compensator axis and blue when perpendicular (remembered by the mnemonic "yellow parallel" for gout). Crystal identification requires experience and appropriate equipment.

Serum uric acid measurement supports but cannot confirm or exclude the diagnosis of acute gout, representing a common diagnostic pitfall. Paradoxically, serum uric acid may be normal or even low during an acute attack due to the uricosuric effect of inflammatory cytokines. Conversely, most individuals with hyperuricemia never develop gout. Therefore, a normal serum uric acid does not exclude gout, and an elevated level does not prove it. Serum uric acid is more valuable for monitoring urate-lowering therapy than for diagnosis. If measured during an acute attack, the result should be confirmed several weeks later when inflammation has resolved.

Clinical criteria may support a presumptive diagnosis of gout when synovial fluid analysis is not feasible, though crystal identification remains the gold standard. The 2015 ACR/EULAR gout classification criteria assign points across clinical, laboratory, and imaging domains, with a score of 8 or more out of 23 points indicating gout. Typical clinical features include involvement of the first MTP joint, rapid onset reaching maximum severity within 24 hours, complete resolution between attacks, and overlying erythema. Imaging evidence of urate deposition on ultrasound (double contour sign over cartilage) or dual-energy CT (color-coded urate deposits) provides strong support. Serum uric acid above 10 mg/dL adds points, while levels below 4 mg/dL subtract points. These criteria are designed for classification rather than diagnosis but may guide clinical decision-making.

Advanced imaging modalities increasingly contribute to gout diagnosis and assessment of urate burden. Ultrasound demonstrates the double contour sign, a hyperechoic band over the surface of hyaline cartilage representing surface urate crystal deposition, which is highly specific for gout. Aggregates of crystals within the joint appear as hyperechoic foci, and tophi show characteristic heterogeneous echotexture with hypoechoic rim. Dual-energy CT exploits the differential X-ray attenuation of urate at two energy levels to produce color-coded images specifically identifying urate deposits, with high sensitivity for tophi and joint crystal deposition. Conventional radiography shows characteristic findings in chronic gout, including punched-out erosions with sclerotic margins and overhanging edges, relative preservation of joint space, and soft tissue tophi that may calcify. These radiographic changes require years to develop and are absent in early disease.

<image>Panel A: Polarized microscopy of synovial fluid demonstrating needle-shaped monosodium urate crystals within a neutrophil, with compensator showing yellow color when crystal is parallel to axis (negative birefringence), with diagram explaining the birefringence concept. Panel B: Clinical diagnostic approach flowchart showing arthrocentesis as gold standard, with crystal identification confirming diagnosis, and alternative pathway using clinical criteria when joint aspiration not possible. Panel C: Dual-energy CT image showing color-coded urate deposits (typically displayed in green) around the first MTP joint and other foot joints, demonstrating the ability to visualize crystal burden. Panel D: Radiographic findings in chronic tophaceous gout showing punched-out erosions with overhanging edges (Martel sign), preserved joint space, and soft tissue tophi, with comparison to rheumatoid arthritis erosions.</image>

V. Management of Acute Gout

Acute gout treatment aims to rapidly reduce inflammation and pain, with several effective options available and selection guided by patient comorbidities, contraindications, and preferences. Treatment should begin as soon as possible after attack onset, as earlier intervention produces faster resolution. Nonsteroidal anti-inflammatory drugs (NSAIDs) at full anti-inflammatory doses represent a first-line option in patients without contraindications, with naproxen 500 mg twice daily, indomethacin 50 mg three times daily, or equivalent doses of other NSAIDs used for 5-7 days or until attack resolution. NSAIDs are contraindicated in patients with chronic kidney disease, heart failure, gastrointestinal bleeding risk, or concurrent anticoagulation, limiting their use in many gout patients.

Colchicine represents another first-line option, providing effective anti-inflammatory activity through inhibition of neutrophil functions including microtubule assembly, chemotaxis, and inflammasome activation. Low-dose colchicine is now preferred over traditional high-dose regimens, which produced unacceptable gastrointestinal toxicity. The current recommended acute regimen is 1.2 mg followed by 0.6 mg one hour later, for a total of 1.8 mg on day one, with 0.6 mg once or twice daily continued until attack resolution. This regimen is effective when initiated within 24-36 hours of attack onset but less effective for established attacks. Colchicine requires dose adjustment in renal impairment and has significant drug interactions with strong CYP3A4 inhibitors (clarithromycin, cyclosporine) that can cause life-threatening toxicity.

Glucocorticoids provide an effective alternative when NSAIDs and colchicine are contraindicated or ineffective, making them particularly useful for patients with renal impairment, heart failure, or multiple comorbidities. Oral prednisone at 30-40 mg daily tapered over 10-14 days is a typical regimen. Intramuscular or intravenous methylprednisolone offers alternatives when oral administration is not possible. Intra-articular corticosteroid injection is highly effective for monoarticular gout when the joint is accessible and infection has been excluded; this approach provides rapid relief with minimal systemic exposure. ACTH (corticotropin) injection is occasionally used but is expensive and less readily available.

Interleukin-1 inhibitors, specifically anakinra (IL-1 receptor antagonist) and canakinumab (anti-IL-1beta monoclonal antibody), represent biologic options for patients with refractory or difficult-to-treat gout. These agents directly target the key cytokine driving gouty inflammation and provide rapid, effective relief. Anakinra at 100 mg daily subcutaneously for 3 days is used off-label for acute gout, while canakinumab 150 mg as a single subcutaneous injection is approved in some countries. IL-1 inhibitors are typically reserved for patients who have failed or cannot tolerate conventional therapies. Important management principles include avoiding initiation or dose changes of urate-lowering therapy during an acute attack (which can prolong the attack) and not stopping ongoing urate-lowering therapy during an attack.

<image>Panel A: Acute gout treatment algorithm showing first-line options (NSAIDs, colchicine, glucocorticoids) with selection based on patient comorbidities, second-line options (IL-1 inhibitors), and combination therapy for severe attacks. Panel B: Colchicine mechanism of action diagram showing microtubule disruption inhibiting neutrophil chemotaxis and phagocytosis, and inflammasome inhibition reducing IL-1beta release. Panel C: Contraindications and considerations comparison showing NSAIDs (renal disease, heart failure, GI bleeding), colchicine (severe renal impairment, drug interactions), and glucocorticoids (diabetes, infection risk), guiding agent selection. Panel D: Intra-articular injection technique for first MTP joint showing needle approach, aspiration of inflammatory fluid, and corticosteroid injection, with expected response timeline.</image>

VI. Urate-Lowering Therapy

Urate-lowering therapy (ULT) aims to reduce serum uric acid below the saturation threshold, typically targeting levels below 6 mg/dL (or below 5 mg/dL for patients with tophi) to dissolve existing crystals and prevent new crystal formation. Indications for initiating ULT include recurrent gout attacks (two or more per year), tophi, gouty arthropathy with radiographic damage, and presence of urolithiasis. ULT may be considered after even a single attack in patients with very high uric acid levels, chronic kidney disease, or limited treatment options for acute attacks. The decision to start ULT should involve shared decision-making with the patient, who must understand the lifelong commitment required.

Xanthine oxidase inhibitors represent the first-line ULT class, reducing uric acid production by blocking the enzyme that converts hypoxanthine to xanthine and xanthine to uric acid. Allopurinol, a purine analog, has been used for over 50 years and remains the most commonly prescribed ULT. Starting dose is 100 mg daily (50 mg in chronic kidney disease), with gradual titration by 50-100 mg increments every 2-4 weeks to achieve target uric acid. Most patients require 300-400 mg daily, though doses up to 800 mg may be needed. Allopurinol hypersensitivity syndrome is a rare but severe reaction featuring rash, fever, hepatitis, and multiorgan failure, associated with HLA-B5801 (prevalent in certain Asian populations). Screening for HLA-B5801 is recommended in high-risk populations before starting allopurinol. Febuxostat, a non-purine selective xanthine oxidase inhibitor, represents an alternative, starting at 40 mg daily with potential increase to 80 mg.

Uricosuric agents increase renal uric acid excretion by inhibiting the URAT1 transporter in the proximal tubule and represent an alternative or add-on to xanthine oxidase inhibitors. Probenecid, the most widely available uricosuric, is started at 250 mg twice daily and titrated to a maximum of 1 g twice daily. Adequate hydration is essential to prevent uric acid crystallization in the urinary tract. Uricosurics are relatively contraindicated in patients with nephrolithiasis, uric acid overproduction, or significantly reduced renal function (creatinine clearance less than 50 mL/min). Lesinurad, a URAT1 inhibitor, was approved for use in combination with a xanthine oxidase inhibitor but has limited availability.

Pegloticase, a pegylated recombinant uricase enzyme that converts uric acid to allantoin, represents a biological option for refractory gout unresponsive to conventional ULT. Administered as an intravenous infusion every two weeks, pegloticase can dramatically lower serum uric acid to undetectable levels and rapidly dissolve tophi. However, immunogenicity leading to anti-drug antibodies causes loss of efficacy in approximately 40-50% of patients, with antibody formation also associated with infusion reactions. Co-administration of immunosuppression (methotrexate) improves response durability. Pegloticase is reserved for patients with severe gout who have failed or cannot tolerate standard therapy. Prophylaxis against gout flares during ULT initiation is essential, as mobilization of crystal deposits frequently triggers attacks.

<image>Panel A: Urate-lowering therapy algorithm showing first-line xanthine oxidase inhibitors (allopurinol or febuxostat) with treat-to-target approach to reach serum uric acid below 6 mg/dL, and options for inadequate response (dose increase, add uricosuric, switch agent, or pegloticase for refractory disease). Panel B: Allopurinol dosing chart showing starting dose (100 mg daily, 50 mg in CKD), titration schedule (increase by 50-100 mg every 2-4 weeks), target serum uric acid (less than 6 mg/dL), and maximum dose (800 mg daily). Panel C: Xanthine oxidase inhibitor mechanism showing blockade at the hypoxanthine to xanthine and xanthine to uric acid conversion steps, with allopurinol metabolized to oxypurinol which also inhibits the enzyme. Panel D: Pegloticase mechanism showing enzymatic conversion of uric acid to allantoin, with infusion schedule, efficacy outcomes (tophi resolution timeline), and immunogenicity concerns.</image>

VII. Gout Flare Prophylaxis and Lifestyle Modification

Gout flare prophylaxis during ULT initiation is essential, as the mobilization of crystal deposits during uric acid lowering frequently triggers attacks that can discourage patients from continuing therapy. Prophylaxis is typically continued for at least 3-6 months after achieving target serum uric acid, with longer duration recommended for patients with tophi or frequent prior attacks. Low-dose colchicine at 0.5-0.6 mg once or twice daily is the preferred prophylactic agent. Alternatively, low-dose NSAIDs (naproxen 250 mg twice daily) may be used in patients without NSAID contraindications. Low-dose prednisone (5 mg or less daily) represents an option when colchicine and NSAIDs are contraindicated. Despite prophylaxis, some breakthrough flares may occur and should not prompt discontinuation of ULT.

Dietary modifications can modestly reduce serum uric acid and may reduce attack frequency, though their impact is generally insufficient for adequate disease control without pharmacological therapy. Patients should limit consumption of high-purine foods including organ meats (liver, kidney), certain seafood (anchovies, sardines, mussels, scallops), and red meat. Moderate purine foods (poultry, fish, legumes, mushrooms) need not be strictly avoided but should be consumed in moderation. Alcohol, particularly beer and spirits, should be limited or avoided, as alcohol increases uric acid production and impairs excretion. Wine appears to have less effect on uric acid than beer or spirits. Fructose-containing beverages (soft drinks, fruit juices) should be avoided. Dairy products, particularly low-fat dairy, may have a protective effect.

Weight management and management of metabolic comorbidities contribute to comprehensive gout care. Weight loss in obese patients can lower serum uric acid and may reduce gout attacks, though the effect is modest. The Mediterranean and DASH (Dietary Approaches to Stop Hypertension) diets are associated with lower gout risk and provide cardiovascular benefits. Metabolic syndrome components (hypertension, dyslipidemia, insulin resistance) should be aggressively managed. When treating hypertension, avoiding thiazide and loop diuretics if possible reduces hyperuricemia; losartan has mild uricosuric properties making it a potentially favorable choice. For dyslipidemia, fenofibrate has uricosuric effects and may be preferred in patients with hypertriglyceridemia. Adequate hydration promotes uric acid excretion.

Patient education and shared decision-making are essential for successful long-term gout management, given the chronic nature of the disease and need for lifelong therapy. Patients should understand that gout is a chronic disease requiring ongoing management rather than episodic treatment of attacks. The concept of crystal dissolution taking months to years helps set expectations about the time required to achieve gout control. Patients should be informed about triggers that may precipitate attacks, including dietary indiscretions, alcohol, dehydration, and acute illnesses. Adherence to ULT is challenging, with many patients discontinuing therapy, particularly after attacks cease; addressing barriers to adherence improves outcomes. Regular monitoring of serum uric acid guides therapy adjustments.

<image>Panel A: Flare prophylaxis regimen showing colchicine 0.5-0.6 mg once or twice daily as preferred agent, duration of 3-6 months minimum after achieving target uric acid, and alternatives (low-dose NSAIDs, low-dose prednisone) for patients with colchicine contraindications. Panel B: Dietary recommendations infographic showing foods to avoid (organ meats, shellfish, beer, sugar-sweetened beverages), foods to limit (red meat, spirits), and beneficial foods (low-fat dairy, water, coffee, cherries) with relative impact on serum uric acid. Panel C: Medication review checklist showing drugs that increase uric acid (thiazides, loop diuretics, low-dose aspirin, cyclosporine) and alternatives or considerations (losartan has uricosuric effect, fenofibrate has uricosuric effect). Panel D: Patient education key points diagram covering chronic disease concept, need for lifelong ULT, expected timeline for crystal dissolution, attack triggers, and adherence importance.</image>

VIII. Calcium Pyrophosphate Deposition Disease

Calcium pyrophosphate deposition (CPPD) disease encompasses a spectrum of manifestations resulting from deposition of calcium pyrophosphate dihydrate crystals in articular and periarticular tissues. Chondrocalcinosis, the radiographic finding of calcification within hyaline or fibrocartilage, is often asymptomatic and may be an incidental finding, particularly in elderly individuals. Acute CPP crystal arthritis, formerly called pseudogout, presents as acute inflammatory arthritis resembling gout. Chronic CPP crystal inflammatory arthritis may mimic rheumatoid arthritis. Osteoarthritis with CPPD refers to degenerative joint disease in the setting of crystal deposition, which may accelerate cartilage damage. Understanding this nomenclature and disease spectrum is important for accurate diagnosis and management.

The pathogenesis of CPPD involves local factors promoting crystal formation within cartilage, with subsequent shedding of crystals into the joint space triggering inflammation. Inorganic pyrophosphate, a byproduct of numerous metabolic reactions, is produced within cartilage and normally regulated by enzymes including alkaline phosphatase. Increased pyrophosphate production or decreased breakdown leads to supersaturation and crystal nucleation. The strong association with aging reflects the cumulative effects of cartilage damage and altered pyrophosphate metabolism. Secondary causes of CPPD should be considered, particularly in patients presenting at younger ages. These include primary hyperparathyroidism (most common secondary cause), hemochromatosis, hypomagnesemia, hypophosphatasia, and familial forms with early-onset disease.

Acute CPP crystal arthritis (pseudogout) presents with rapid-onset monoarticular or oligoarticular inflammatory arthritis, most commonly affecting the knee, which distinguishes it from gout's predilection for the first MTP joint. The wrist, ankle, and shoulder are also frequently involved. Attacks may be triggered by acute illness, surgery, or trauma. The clinical presentation resembles gout with joint pain, swelling, warmth, and erythema, making crystal identification essential for differentiation. Synovial fluid analysis reveals inflammatory fluid with CPP crystals that appear as rhomboid or rod-shaped structures with weak positive birefringence (blue when parallel to the compensator axis, opposite to MSU crystals). Radiographs may show chondrocalcinosis, particularly in the knee menisci, triangular fibrocartilage of the wrist, and pubic symphysis.

Treatment of acute CPP crystal arthritis follows similar principles to acute gout, as both conditions involve crystal-induced inflammation. Intra-articular corticosteroid injection is highly effective for monoarticular disease, providing rapid relief with minimal systemic effects. Oral NSAIDs or colchicine may be used when multiple joints are affected or intra-articular injection is not feasible. Systemic corticosteroids provide an alternative for patients with contraindications to NSAIDs and colchicine. Unlike gout, there is no proven therapy to reduce CPP crystal burden or prevent disease progression. Secondary causes should be identified and treated when present (parathyroidectomy for primary hyperparathyroidism, iron reduction for hemochromatosis, magnesium supplementation for hypomagnesemia). Low-dose colchicine may be used as prophylaxis for patients with frequent attacks.

<image>Panel A: CPPD disease spectrum diagram showing chondrocalcinosis (often asymptomatic), acute CPP crystal arthritis (inflammatory attacks), chronic inflammatory arthritis, and OA with CPPD, with overlapping presentations indicated. Panel B: Radiograph of knee showing meniscal and hyaline cartilage calcification (chondrocalcinosis), with additional radiograph showing wrist triangular fibrocartilage calcification. Panel C: Polarized microscopy comparison of MSU crystals (needle-shaped, strongly negative birefringent, yellow parallel) versus CPP crystals (rhomboid or rod-shaped, weakly positive birefringent, blue parallel), with memory aids for identification. Panel D: Secondary CPPD causes checklist showing hyperparathyroidism (check calcium, PTH), hemochromatosis (check ferritin, transferrin saturation), hypomagnesemia (check magnesium), and hypophosphatasia (check alkaline phosphatase), with recommended screening tests.</image>

IX. Basic Calcium Phosphate Disease

Basic calcium phosphate (BCP) crystal deposition causes a distinct spectrum of musculoskeletal disease, with hydroxyapatite being the most important BCP crystal. Unlike MSU and CPP crystals, BCP crystals are too small to be identified by standard light microscopy and require specialized techniques (electron microscopy, alizarin red staining) for detection. Calcific tendinitis, most commonly affecting the rotator cuff (supraspinatus tendon), results from BCP crystal deposition within tendons, presenting with acute severe shoulder pain when crystals trigger inflammation or are resorbed. Radiographs show calcific deposits within the tendon. Treatment includes NSAIDs, subacromial corticosteroid injection, ultrasound-guided lavage and aspiration of deposits, or rarely surgical removal for refractory cases. Most cases resolve spontaneously over weeks to months.

Milwaukee shoulder syndrome represents a destructive arthropathy associated with BCP crystal deposition, typically occurring in elderly women and causing rapid joint destruction. The shoulder is most commonly affected, with massive rotator cuff tear, joint instability, and extensive cartilage and bone destruction. Synovial fluid is typically non-inflammatory with a low cell count but contains numerous BCP crystal clusters identifiable by alizarin red staining. The pathogenic mechanism involves BCP crystal stimulation of synovial cells to produce collagenases and other enzymes that degrade cartilage and periarticular structures. Similar BCP-associated destructive arthropathy can affect other joints, particularly the knee.

Oxalate crystal deposition occurs primarily in patients with primary hyperoxaluria or end-stage renal disease, particularly those on long-term hemodialysis. Calcium oxalate crystals deposit in joints and soft tissues, causing acute inflammatory arthritis or chronic arthropathy. Crystals appear as bipyramidal (envelope-shaped) structures with positive birefringence on polarized microscopy. Treatment of underlying metabolic derangement is essential when possible. Cholesterol crystals may be found in chronically inflamed joints and bursae (particularly in rheumatoid arthritis) but are typically not primary pathogens; they appear as large, flat, notched rectangular plates with negative birefringence.

Crystal arthropathies share common inflammatory mechanisms centered on innate immune activation, providing a unifying framework for understanding these diverse conditions. All pathogenic crystals can activate the NLRP3 inflammasome with subsequent IL-1beta release, explaining why similar treatments (NSAIDs, colchicine, corticosteroids, and potentially IL-1 inhibitors) are effective across different crystal types. The particulate nature of crystals allows phagocytosis and lysosomal damage, triggering intracellular danger signals. Crystal surface properties, coating proteins, and local tissue factors all influence inflammatory potential. Understanding these shared mechanisms has facilitated development of targeted therapies and provides rationale for treatment approaches across the spectrum of crystal-induced disease.

<image>Panel A: Calcific tendinitis imaging showing plain radiograph with supraspinatus calcification, ultrasound demonstrating hyperechoic focus with acoustic shadowing in the tendon, and clinical photograph of painful arc during shoulder abduction. Panel B: Crystal identification comparison showing morphology, birefringence, and typical clinical associations for MSU (needle, strongly negative, gout), CPP (rhomboid, weakly positive, pseudogout), BCP (too small for light microscopy, calcific tendinitis/Milwaukee shoulder), and calcium oxalate (bipyramidal, positive, dialysis/hyperoxaluria). Panel C: Milwaukee shoulder syndrome features showing massive rotator cuff tear on MRI, large non-inflammatory effusion, joint destruction on radiograph, and typical patient demographics (elderly woman). Panel D: Common inflammatory pathway diagram showing multiple crystal types converging on NLRP3 inflammasome activation, IL-1beta release, and neutrophil-mediated inflammation, with therapeutic intervention points.</image>

X. Special Populations and Comorbidities

Gout in the elderly presents distinct challenges due to increased prevalence, comorbidities limiting treatment options, and atypical presentations. The high prevalence of renal impairment in elderly patients restricts NSAID use and requires colchicine dose adjustment. Polyarticular presentations are more common in elderly patients, potentially mimicking rheumatoid arthritis or pseudogout. Drug interactions with polypharmacy require careful attention, particularly regarding colchicine interactions with statins and CYP3A4 inhibitors. Glucocorticoids, while effective, pose concerns regarding glucose control, infection risk, and delirium in elderly patients. Allopurinol dosing requires careful initiation and titration with monitoring for hypersensitivity, and HLA-B*5801 testing may be considered given the potentially higher prevalence in some elderly populations.

Gout in patients with chronic kidney disease requires modified management approaches, as renal impairment affects both gout pathophysiology and treatment. Hyperuricemia is nearly universal in advanced CKD, though the relationship between uric acid and kidney disease progression remains debated. NSAIDs are generally contraindicated in significant CKD due to risks of acute kidney injury, fluid retention, and hypertension. Colchicine requires dose reduction and may accumulate with repeated dosing; it should be avoided in severe renal impairment. Corticosteroids, particularly intra-articular injection, become the mainstay of acute treatment. Allopurinol is effective and can be used with dose adjustment starting at 50 mg daily; contrary to previous recommendations, achieving target uric acid often requires doses exceeding those predicted by creatinine clearance. Febuxostat does not require dose adjustment for mild-moderate CKD.

Women with gout represent an underrecognized population, as the disease is less common than in men but may be underdiagnosed due to lower clinical suspicion. Postmenopausal women lack estrogen's uricosuric effect, and gout incidence rises substantially after menopause. Diuretic use for hypertension is a common contributing factor in women. Presentations may be atypical, with polyarticular involvement more common and less frequent first MTP involvement. The association with metabolic syndrome components is strong. Treatment approaches are generally similar to men, though pregnancy considerations require attention in premenopausal women (colchicine and NSAIDs should be avoided, with glucocorticoids preferred for acute attacks).

Cardiovascular considerations in gout management have gained increasing attention given the strong association between gout and cardiovascular disease. Gout patients have elevated risks of myocardial infarction, heart failure, and cardiovascular mortality independent of traditional risk factors. Whether uric acid itself contributes to cardiovascular risk or merely serves as a marker of metabolic derangement remains debated. Febuxostat's cardiovascular safety has been questioned following the CARES trial, which found higher cardiovascular mortality compared to allopurinol in patients with established cardiovascular disease. Current recommendations favor allopurinol as first-line ULT in patients with significant cardiovascular disease. Comprehensive cardiovascular risk management, including treatment of hypertension, dyslipidemia, and diabetes, is essential in gout patients.

<image>Panel A: Elderly patient management considerations diagram showing increased comorbidities limiting treatment options, atypical polyarticular presentations, drug interactions with polypharmacy, and modified treatment approach favoring corticosteroids and careful allopurinol initiation. Panel B: CKD and gout treatment modifications showing NSAID contraindication, colchicine dose reduction requirements, allopurinol starting at 50 mg with slow titration, and corticosteroids as preferred acute treatment with renal dosing adjustments. Panel C: Gout in women infographic showing postmenopausal predominance, diuretic use as risk factor, atypical presentations, and treatment considerations including avoidance of colchicine and NSAIDs in pregnancy. Panel D: Cardiovascular risk management showing association between gout and cardiovascular disease, cardiovascular safety considerations for ULT selection (allopurinol preferred in established CVD), and importance of comprehensive cardiovascular risk factor treatment.</image>

Summary

• Hyperuricemia above 6.8 mg/dL results from underexcretion (90%) or overproduction (10%) of uric acid; risk factors include diet, alcohol, obesity, diuretics, and chronic kidney disease
• Acute gout presents with dramatic monoarticular inflammation, classically podagra (first MTP), mediated by NLRP3 inflammasome activation and IL-1beta release
• Definitive diagnosis requires identification of negatively birefringent needle-shaped MSU crystals in synovial fluid; serum uric acid may be normal during acute attacks
• Acute gout is treated with NSAIDs, colchicine (low-dose regimen), or glucocorticoids; agent selection depends on patient comorbidities and contraindications
• Urate-lowering therapy with xanthine oxidase inhibitors (allopurinol, febuxostat) targets serum uric acid below 6 mg/dL; prophylaxis against flares is essential during initiation
• CPPD (pseudogout) presents with acute arthritis, typically affecting the knee; CPP crystals are rhomboid with weak positive birefringence
• Secondary causes of CPPD include hyperparathyroidism, hemochromatosis, and hypomagnesemia; treatment is symptomatic as no crystal-dissolving therapy exists
• BCP crystals cause calcific tendinitis and Milwaukee shoulder syndrome; crystals are too small for light microscopy identification
• Crystal identification on synovial fluid analysis is the gold standard for diagnosis of all crystal arthropathies

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown